Quantum BioPharma signs Thermo Fisher clinical research unit contract to launch Phase 2 MS trial
QNTM•Quantum BioPharma signed a study start-up agreement with Thermo Fisher’s PPD clinical research unit for a Phase 2 trial of Lucid-MS in progressive multiple sclerosis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety and tolerability after FDA clearance to proceed.
1. Trial start-up agreement
Quantum BioPharma signed an agreement with Thermo Fisher’s PPD clinical research unit to begin formal start-up work for a Phase 2 trial of Lucid-MS in progressive multiple sclerosis. The randomized, double-blind, placebo-controlled study will assess efficacy, safety and tolerability using clinical and radiological endpoints.
